Yükleniyor... / Loading...
This study looks at the use of methylation markers for the early detection of lung cancer and for monitoring minimal residual disease (MRD) after treatment. It enrolls patients aged 18 to 85 with histopathologically or clinically diagnosed non-small cell lung cancer who are considered suitable for surgery. It is an observational study with no assigned phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosed with non-small cell lung cancer (NSCLC) by histopathology/clinical diagnosis. * Age 18-85 years old. * Lung cancer patients who are determined by clinicians to be eligible for surgical treatment. * ECOG score ≤ 2, with an expected survival period of ≥ 6 months, and having signed the informed consent form. * The subjects should have clear case information, including age, gender, and clinical diagnosis, etc. Exclusion Criteria: * Patients with a history of other malignant tumors or autoimmune diseases. * Those with severe heart, lung or vascular diseases that make them unable to tolerate surgery. * Pregnant or lactating women. * Patients who may be unable to complete follow-up during the study, as well as other factors that the researcher deems inappropriate for participation in the study. * Incomplete clinical or follow-up information.